Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update Highlights • FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA) • FDA agreed that a single pivotal Phase 3 trial plus confirmatory...